You are here: Home » Companies » News
Can Fin Homes stock under pressure second day in row, sheds 4% on BSE
Business Standard

Growth forecast in US market set to drive gains for Cipla stock

Street remains bullish on India prospects, regulatory headwinds for Goa site continue

Topics
Cipla | Nifty Pharma | Pharma stocks

Ram Prasad Sahu 



Cipla, Cipla logo, Cipla headquarters
Cipla is the only generic player in the market and had launched the drug seven months earlier in February

The stock of major was the biggest gainer in the and Healthcare indices, jumping about 5.5 per cent in trade on Tuesday. The Healthcare index also saw the largest increase among sectoral indices with a rise of about 3 per cent.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Tue, September 20 2022. 21:21 IST

RECOMMENDED FOR YOU

.